Virginia Commonwealth University

Sanford Burnham Prebys Medical Discovery Institute

Luni Emdad

Paul B Fisher

Swadesh K Das

Mitchell E Menezes

Maurizio Pellecchia

Devanand Sarkar

Jun Wei

Praveen Bhoopathi

Timothy P Kegelman

Surya K De

Bainan Wu

Upneet Sokhi

Anjan K Pradhan

Xiang-yang Wang

In various aspects, the present disclosure provides polynucleotides encoding a fusion protein, as well as vectors, cells, and compositions comprising the same. In embodiments, the fusion protein includes an insulin signal peptide and an MDA-7/IL-24 protein. Methods of using the polynucleotides, vectors, cells, and compositions, such as in the treatment or prevention of cancer, are also provided.

MDA-7/IL-24 secretory variants and methods of use

Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Inhibitors of cancer invasion, attachment, and/or metastasis

Recombinant therapeutic cytokines ('therakines') for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 ('M4') not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Recombinant cancer therapeutic cytokine

Growing community of inventors

Richmond, VA, United States of America

Luni Emdad